This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, C. K.
Right arrow Articles by Hospenthal, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, C. K.
Right arrow Articles by Hospenthal, D. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 4002-4005, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4002-4005.2004

Determination of Susceptibilities of 26 Leptospira sp. Serovars to 24 Antimicrobial Agents by a Broth Microdilution Technique

Clinton K. Murray and Duane R. Hospenthal*

Infectious Disease Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas

Received 7 April 2004/ Returned for modification 6 June 2004/ Accepted 23 June 2004


arrow
ABSTRACT
 
The MICs of 24 antimicrobials for 26 Leptospira spp. serovars were determined using a broth microdilution technique. The MICs at which 90% of isolates tested were inhibited (MIC90s) of cefepime, imipenem-cilastatin, erythromycin, clarithromycin, and telithromycin were all ≤0.01 µg/ml. The MIC90s of amoxicillin, aztreonam, cefdinir, chloramphenicol, and penicillin G were ≥3.13 µg/ml. Many antimicrobials have excellent in vitro activity against Leptospira.


arrow
TEXT
 
Leptospirosis is a worldwide zoonotic infection that is predominantly found in tropical climates. The genus Leptospira consists of 16 species and over 250 serovars, with the virulent strains producing infections that range from clinically inapparent to life threatening. The typical symptomatic presentation of leptospirosis is a mild febrile illness without pathognomonic findings. Definitive diagnosis relies upon either culture which has a low yield and requires incubation of 4 to 6 weeks or serological testing of acute- and convalescent-phase samples. Therefore, initial therapy of leptospirosis is often empirical, based upon a broad differential diagnosis that includes leptospirosis and other etiologies of acute febrile illness in the community.

Clinical trials of antimicrobial agents against leptospirosis are limited to penicillin, doxycycline, and ceftriaxone (4, 7, 11, 15). Although no survival benefit has been shown with these agents, symptom improvement, including resolution of fever and leptospiruria, has been documented. The ever-growing armamentarium of antimicrobial agents used as empirical therapies for acute febrile illnesses necessitates the assessment of newer antimicrobial agents against leptospirosis. In vitro antibiotic susceptibility testing, typically done on a limited scale using macrodilution techniques and small numbers of serovars, has been reported (3, 6, 8, 10, 12-14). We have developed an in vitro broth microdilution technique by which a more efficient evaluation of a greater number of antimicrobial agents and Leptospira serovars can be accomplished (9). In this study we assess the in vitro activity of 24 antimicrobial agents against 26 Leptospira serovars.

(This work was presented in part at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Philadelphia, Penn., December 2003.)

Twenty-six Leptospira serovars, representing seven species and 18 serogroups, were obtained from the Veterinary Command Food and Drug Analysis Laboratory, Fort Sam Houston, Texas (Table 1). These strains originated at the USDA National Veterinary Services Laboratories, Ames, Iowa. Although the majority of these were initially recovered from human infections, all have been maintained by subculture as laboratory strains for many years. The organisms were maintained and the inocula were prepared as previously described (9).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Strains of Leptospira species tested for susceptibility to various antimicrobial agents

Broth microdilution susceptibility testing was performed as previously reported with antibiotic concentrations ranging from 25.0 to 0.01 µg/ml (U/ml for penicillin G) (9). Amoxicillin, ampicillin, cefotaxime, chloramphenicol, doxycycline, erythromycin, penicillin G, and tetracycline were purchased from Sigma-Aldrich (St. Louis, Mo.). Other antibiotics were obtained from their manufacturers (cefdinir and clarithromycin from Abbott Laboratories, Abbott Park, Ill.; telithromycin from Aventis, Bridgewater, N.J.; ciprofloxacin and moxifloxacin from Bayer Corporation, West Haven, Conn.; aztreonam, cefepime, garenoxacin, and gatifloxacin from Bristol-Myers Squibb, Wallingford, Conn.; ceftriaxone from Hoffmann-La Roche Inc., Nutley, N.J.; cefoxitin, ertapenem, imipenem, and cilastatin from Merck & Co., Inc., Rahway, N.J.; levofloxacin from Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J.; and ampicillin, sulbactam, and azithromycin from Pfizer, Groton, Conn.). Ampicillin-sulbactam and imipenem-cilastatin were combined in 2:1 and 1:1 ratios, respectively, with the reported MICs being based on the concentration of the first agent in each combination. Each serovar-drug combination was tested in triplicate, and median MICs were used for comparisons. Cumulative susceptibility results across all serovars are expressed as MIC90, the concentration at which 90% of the Leptospira isolates are inhibited.

The median MICs from three experiments using the strains indicated in Table 1 are reported in Table 2. The observed reproducibility of drug-serovar combinations revealed that 84% (527 of 624) of test results fell within two dilutions of each other. The reproducibility increases to 94% if amoxicillin, ampicillin, and penicillin G are excluded from this comparison.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Susceptibility of Leptospira strains to 24 antimicrobial agents or combinations of agents

Ampicillin-sulbactam, the carbapenems, cefepime, cefotaxime, cefoxitin, ceftriaxone, the fluoroquinolones, the macrolides, and telithromycin all produced MIC90s of ≤0.39 µg/ml. Cefepime, clarithromycin, erythromycin, imipenem-cilastatin, erythromycin, and telithromycin were all found to have MIC90s below the limit of testing (≤0.01 µg/ml). The MIC90s of amoxicillin, aztreonam, cefdinir, chloramphenicol, and penicillin G across serovars were ≥3.13 µg/ml.

Delays inherent in the diagnosis of leptospirosis, a potentially fatal infection, often dictate empirical therapy for acute febrile illness. As the differential diagnosis of an acute febrile illness in any particular setting may be expansive, numerous antimicrobial agents are often used as initial therapies. Only three drugs have been evaluated for leptospirosis in randomized human trials (4, 7, 11, 15). Determination of the antileptospiral activity of newer agents is needed. Currently there is no standard method to assess in vitro antimicrobial agents for antileptospiral activity; however, we have recently described a broth microdilution method which is more rapid than the traditional macrodilution method (9). Our assessment by broth microdilution of 24 antimicrobial agents against 26 Leptospira serovars found that many antimicrobial agents have excellent in vitro activity.

Included in our testing were the traditional antileptospiral drugs penicillin G, ceftriaxone, and doxycycline and representative agents from many other classes of agents. As classes of antimicrobial agents, carbapenems, cephalosporins (with the exception of cefdinir), fluoroquinolones, and macrolides (and telithromycin) had lower MICs than the traditional agents. All agents with the exception of aztreonam had MICs equal to or less than that of penicillin G, the accepted treatment alternative for severe disease. The overall reproducibility seen in our study was excellent, although amoxicillin, ampicillin, and penicillin G had greater variability than the other antimicrobial agents tested. Serovar-specific diagnosis is virtually never available for therapy of acute infection, so an assortment of Leptospira spp. were included in our study to allow observation of potential strain-to-strain and species-to-species variability. We noted no clinically significant strain-to-strain or species-to-species variability.

A variety of antimicrobials have shown variable therapeutic activity in small in vitro and in vivo (animal) studies; however, these studies are limited by the numbers of antimicrobials and/or isolates of Leptospira spp. examined at one time (1-3, 5, 6, 8, 10, 12-14, 16). Through our broth microdilution study, we delivered reproducible results and allowed more convenient testing with greater throughput than previous macrodilution methods. Presently correlation of in vitro susceptibility to outcome is lacking in treatment trials for leptospirosis. Future study, including animal and human treatment or prophylaxis trials, can now be pursued to determine if any of these agents will be useful in the therapy of leptospirosis.


arrow
ACKNOWLEDGMENTS
 
This work was supported in part by a grant from Abbott Laboratories.

The views expressed herein are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. government.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Infectious Disease (MCHE-MDI), Brooke Army Medical Center, 3851 Roger Brooke Dr., Fort Sam Houston, TX 78234. Phone: (210) 916-4355. Fax: (210) 916-0388. E-mail: Duane.Hospenthal{at}amedd.army.mil. Back


arrow
REFERENCES
 
    1
  1. Alexander, A., and R. L. Rule. 1986. Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis. Antimicrob. Agents Chemother. 30:835-839.[Abstract/Free Full Text]
    2. 2
  2. Alt, D. P., and C. A. Bolin. 1996. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am. J. Vet. Res. 57:59-62.[Medline]
    3. 3
  3. Broughton, E. S., and L. E. Flack. 1986. The susceptibility of a strain of Leptospira interrogans serogroup icterohaemorrhagiae to amoxycillin, erythromycin, lincomycin, tetracycline, oxytetracycline and minocycline. Zentbl. Bakteriol. Mikrobiol. Hyg. Ser. A 261:425-431.
    4. 4
  4. Edwards, C. N., G. D. Nicholson, T. A. Hassell, C. O. R. Everard, and J. Callender. 1988. Penicillin therapy in icteric leptospirosis. Am. J. Trop. Med. Hyg. 39:388-390.
    5. 5
  5. Faine, S., and W. J. Kaipainen. 1955. Erythromycin in experimental leptospirosis. J. Infect. Dis. 57:146-151.
    6. 6
  6. Hospenthal, D. R., and C. K. Murray. 2003. In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics. Antimicrob. Agents Chemother. 47:2646-2648.[Abstract/Free Full Text]
    7. 7
  7. McClain, B. L., W. R. Ballou, S. M. Harrison, and D. L. Steinweg. 1984. Doxycycline therapy for leptospirosis. Ann. Intern. Med. 100:696-698.
    8. 8
  8. Murgia, R., and M. Cinco. 2001. Sensitivity of Borrelia and Leptospira to quinupristin-dalfopristin (Synercid) in vitro. New Microbiol. 24:193-196.[Medline]
    9. 9
  9. Murray, C. K., and D. R. Hospenthal. 2004. Broth microdilution susceptibility testing for Leptospira spp. Antimicrob. Agents Chemother. 48:1548-1552.[Abstract/Free Full Text]
    10. 10
  10. Oie, S., K. Hironaga, A. Koshiro, H. Konishi, and Z. Yoshii. 1983. In vitro susceptibilities of five Leptospira strains to 16 antimicrobial agents. Antimicrob. Agents Chemother. 24:905-908.[Abstract/Free Full Text]
    11. 11
  11. Panaphut, T., S. Domrongkitchaiporn, A. Vibhagool, B. Thinkamrop, and W. Susaengrat. 2003. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin. Infect. Dis. 36:1507-1513.[CrossRef][Medline]
    12. 12
  12. Prescott, J. 1991. Treatment of leptospirosis. Cornell Vet. 81:7-12.[Medline]
    13. 13
  13. Shalit, I., A. Barnea, and A. Shahar. 1989. Efficacy of ciprofloxacin against Leptospira interrogans serogroup icterohaemorrhagiae. Antimicrob. Agents Chemother. 33:788-789.[Abstract/Free Full Text]
    14. 14
  14. Takashima, I., M. Ngoma, and N. Hashimoto. 1993. Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans. Antimicrob. Agents Chemother. 37:901-902.[Abstract/Free Full Text]
    15. 15
  15. Watt, G., L. P. Padre, M. L. Tuazon, C. Calubaquib, E. Santiago, C. P. Ranoa, and L. W. Laughlin. 1988. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet 1:433-435.[CrossRef][Medline]
    16. 16
  16. Yoshimori, R. N., H. S. Goldberg, and D. C. Blenden. 1966. Cephalothin in the treatment of experimental leptospirosis in hamsters. Antimicrob. Agents Chemother. 5:450-452.

Antimicrobial Agents and Chemotherapy, October 2004, p. 4002-4005, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4002-4005.2004




This article has been cited by other articles:

  • Ressner, R. A., Griffith, M. E., Beckius, M. L., Pimentel, G., Miller, R. S., Mende, K., Fraser, S. L., Galloway, R. L., Hospenthal, D. R., Murray, C. K. (2008). Antimicrobial Susceptibilities of Geographically Diverse Clinical Human Isolates of Leptospira. Antimicrob. Agents Chemother. 52: 2750-2754 [Abstract] [Full Text]  
  • Moon, J. E., Rivard, R. G., Griffith, M. E., Ressner, R. A., McCall, S., Reitstetter, R. E., Hospenthal, D. R., Murray, C. K. (2007). Effect of timing and duration of azithromycin therapy of leptospirosis in a hamster model. J Antimicrob Chemother 59: 148-151 [Abstract] [Full Text]  
  • Moon, J. E., Ellis, M. C., Griffith, M. E., Hawley, J. S., Rivard, R. G., McCall, S., Hospenthal, D. R., Murray, C. K. (2006). Efficacy of Macrolides and Telithromycin against Leptospirosis in a Hamster Model.. Antimicrob. Agents Chemother. 50: 1989-1992 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, C. K.
Right arrow Articles by Hospenthal, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, C. K.
Right arrow Articles by Hospenthal, D. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»